Global Liver Disease Treatment Market - 2025 -2033
Liver Disease Treatment Market Size & Industry Outlook
The global liver disease treatment market size reached US$ 21.36 billion with rise of US$ 22.70 billion in 2024 is expected to reach US$ 40.94 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033. One of the major drivers of the global liver disease treatment market is increasing awareness and early diagnosis initiatives. Governments, healthcare organizations, and non-profits are actively promoting liver health education and screening programs, leading to earlier detection of conditions like hepatitis B and C, fatty liver disease, and liver cancer. For instance, the World Health Organization (WHO) has launched global hepatitis elimination programs that encourage widespread testing and early treatment. Early diagnosis not only improves patient outcomes but also drives demand for antiviral therapies, liver-protective drugs, and innovative treatments, thereby fueling market growth.
Key Highlights
Drivers: Increasing incidence of liver diseases is significantly driving the liver disease treatment market growth
A key driver of the global liver disease treatment market is the increasing incidence of liver diseases, which has been rising steadily over the past decades due to various lifestyle, environmental, and demographic factors. Conditions such as hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and liver cancer are becoming more prevalent worldwide.
For instance, according to the World Health Organization (WHO), an estimated 296 million people were living with chronic hepatitis B infection in 2022, while hepatitis C affected around 58 million people globally. Additionally, the growing prevalence of obesity and type 2 diabetes has contributed to a surge in NAFLD and MASH cases, which are emerging as major public health concerns. This rising burden of liver diseases increases the demand for effective diagnostics, antiviral therapies, immunomodulators, and novel liver-targeted treatments.
Restraints: Strict regulatory approvals are hampering the growth of the liver disease treatment market
The global liver disease treatment market faces a significant challenge due to strict regulatory approvals from authorities like the FDA and EMA. These regulations ensure drug safety, efficacy, and quality, but can delay the introduction of innovative treatments. For example, antiviral drugs for hepatitis or novel therapies for NASH/MASH require multiple clinical trials and stringent manufacturing standards. This rigorous regulatory environment can limit treatment speed, restrict market growth, and pose financial and operational challenges for pharmaceutical companies in the liver disease treatment sector.
Segmentation Analysis
The global liver disease treatment market is segmented based on treatment type, disease type, route of administration, distribution channel, and region.
Treatment Type: The antiviral drugs from treatment type segment to dominate the liver disease treatment market with a 40.1% share in 2024
The antiviral drug segment is a major driver of the liver disease treatment market due to the high prevalence of viral hepatitis infections worldwide. Chronic hepatitis B and C infections affect hundreds of millions of people globally, creating a persistent demand for effective antiviral therapies. Innovations in direct-acting antivirals (DAAs) have significantly improved cure rates for hepatitis C, while nucleos(t)ide analogs have become the standard of care for hepatitis B, reducing the risk of liver cirrhosis and hepatocellular carcinoma.
For instance, in June 2025, Enanta Pharmaceuticals has received FDA approval for MAVYRET, an oral pangenotypic direct acting antiviral therapy, as the only eight-week treatment for adults and pediatric patients three years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis. The FDA has approved the treatment for viral infections and immunological diseases.
Additionally, government initiatives and WHO-led hepatitis elimination programs are promoting widespread screening and treatment, further boosting the uptake of antiviral drugs. The availability of oral, convenient, and highly effective antiviral regimens has made this segment one of the fastest-growing contributors to the liver disease therapeutics market.
Disease Type:The hepatitis segment is estimated to have a 41.2% of the liver disease treatment market share in 2024
The hepatitis disease type segment drives market growth due to the ongoing global burden of both hepatitis B (HBV) and hepatitis C (HCV) infections. Factors such as unsafe medical practices, blood transfusions, and high-risk behaviors contribute to the continued spread of these viral infections, particularly in developing regions. The rising prevalence of chronic hepatitis increases the demand for early diagnosis, long-term management, and treatment interventions, including antivirals, vaccines, and liver-protective therapies. Public health campaigns, increasing awareness, and government-supported vaccination programs for hepatitis B are also stimulating growth in this segment, making hepatitis-related therapies a cornerstone of the liver disease treatment market.
Geographical Analysis
North America dominates the global liver disease treatment market with a 43.5% in 2024
The liver disease treatment market in North America is primarily driven by the high prevalence of hepatitis C, liver cancer, and non-alcoholic fatty liver disease (NAFLD). Widespread awareness campaigns, advanced healthcare infrastructure, and strong reimbursement policies encourage early diagnosis and treatment. Additionally, continuous investment in research and development of novel antiviral and NASH-targeted therapies fuels market growth.
In the United States, the market is propelled by the high incidence of chronic liver diseases and obesity-related NAFLD/NASH cases. Federal initiatives such as the CDC’s hepatitis screening and elimination programs increase patient identification, leading to greater demand for antiviral drugs, immunosuppressants, and liver-protective therapies. The presence of leading pharmaceutical companies and clinical trial activity also contributes significantly.
For instance, in August 2025, The U.S. Food and Drug Administration has approved Wegovy (semaglutide) injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis (excessive scar tissue in the liver). MASH, also known as nonalcoholic steatohepatitis, is a serious liver disease.
Europe is the second region after North America which is expected to dominate the global liver disease treatment market with a 34.5% in 2024
Europe’s market growth is driven by the aging population, rising liver disease prevalence, and strong government support for healthcare initiatives. Countries like France, Italy, and the UK have implemented nationwide hepatitis vaccination and screening programs. The focus on early diagnosis and treatment of NAFLD/NASH and liver cancer creates steady demand for innovative therapeutics.
In Germany, the market is boosted by well-established healthcare infrastructure, high patient awareness, regulatory approvals and robust reimbursement frameworks. The country’s emphasis on chronic disease management, coupled with widespread hepatitis vaccination programs and access to advanced therapies, supports the adoption of antiviral drugs, biologics, and targeted treatments.
For instance, in August 2025, Madrigal Pharmaceuticals has received conditional marketing authorization from the European Commission for Rezdiffra, a novel therapeutic for metabolic dysfunction-associated steatohepatitis (MASH). The treatment is now the first and only approved therapy in the EU for adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
The Asia Pacific region is the fastest-growing region in the global liver disease treatment market, with a CAGR of 8.1% in 2024
The Asia Pacific market is driven by the high burden of viral hepatitis, particularly HBV and HCV, in countries like China and India. Rapid urbanization, lifestyle changes, and increasing rates of obesity contribute to NAFLD/NASH prevalence. Expanding healthcare access, government-led vaccination campaigns, and rising awareness about liver diseases further accelerate market growth.
Japan’s market growth is supported by the aging population and high prevalence of liver cancer and chronic hepatitis. Strong healthcare infrastructure, early diagnosis programs, and availability of advanced antiviral and immunomodulatory therapies contribute to increasing adoption. Government initiatives to reduce hepatitis-related mortality also enhance treatment uptake.
For instance, in September 2025, Japan's Ministry of Health, Labour and Welfare has approved Bylvay (odevixibat) for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare genetic disorder causing liver damage and potentially liver failure. Symptoms include severe itching, skin mutilation, sleep disruption, irritability, and impaired cognitive and social development. The condition severely impacts quality of life through debilitating symptoms.
Competitive Landscape
Top companies in the liver disease treatment market include AbbVie, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Astellas Pharma Inc., Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Akero Therapeutics and among others.
AbbVie: AbbVie is a key player in the liver disease treatment market, leveraging its strong portfolio of antiviral and liver-targeted therapies to address chronic hepatitis and related conditions. The company’s products, such as Viekira Pak and Mavyret, have been instrumental in providing highly effective treatment options for hepatitis C, offering shorter treatment durations and high cure rates. AbbVie also invests in research and development for emerging liver diseases, including NASH and autoimmune liver disorders, aiming to expand its therapeutic offerings beyond traditional antivirals.
The global liver disease treatment market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
The global liver disease treatment market size reached US$ 21.36 billion with rise of US$ 22.70 billion in 2024 is expected to reach US$ 40.94 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033. One of the major drivers of the global liver disease treatment market is increasing awareness and early diagnosis initiatives. Governments, healthcare organizations, and non-profits are actively promoting liver health education and screening programs, leading to earlier detection of conditions like hepatitis B and C, fatty liver disease, and liver cancer. For instance, the World Health Organization (WHO) has launched global hepatitis elimination programs that encourage widespread testing and early treatment. Early diagnosis not only improves patient outcomes but also drives demand for antiviral therapies, liver-protective drugs, and innovative treatments, thereby fueling market growth.
Key Highlights
- North America dominates the liver disease treatment market with the largest revenue share of 43.5% in 2024.
- The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 8.1% over the forecast period.
- Based on treatment type, antiviral drugs segment led the market with the largest revenue share of 40.1% in 2024.
- The major market players in the AbbVie, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Astellas Pharma Inc., Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Akero Therapeutics and among others.
Drivers: Increasing incidence of liver diseases is significantly driving the liver disease treatment market growth
A key driver of the global liver disease treatment market is the increasing incidence of liver diseases, which has been rising steadily over the past decades due to various lifestyle, environmental, and demographic factors. Conditions such as hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and liver cancer are becoming more prevalent worldwide.
For instance, according to the World Health Organization (WHO), an estimated 296 million people were living with chronic hepatitis B infection in 2022, while hepatitis C affected around 58 million people globally. Additionally, the growing prevalence of obesity and type 2 diabetes has contributed to a surge in NAFLD and MASH cases, which are emerging as major public health concerns. This rising burden of liver diseases increases the demand for effective diagnostics, antiviral therapies, immunomodulators, and novel liver-targeted treatments.
Restraints: Strict regulatory approvals are hampering the growth of the liver disease treatment market
The global liver disease treatment market faces a significant challenge due to strict regulatory approvals from authorities like the FDA and EMA. These regulations ensure drug safety, efficacy, and quality, but can delay the introduction of innovative treatments. For example, antiviral drugs for hepatitis or novel therapies for NASH/MASH require multiple clinical trials and stringent manufacturing standards. This rigorous regulatory environment can limit treatment speed, restrict market growth, and pose financial and operational challenges for pharmaceutical companies in the liver disease treatment sector.
Segmentation Analysis
The global liver disease treatment market is segmented based on treatment type, disease type, route of administration, distribution channel, and region.
Treatment Type: The antiviral drugs from treatment type segment to dominate the liver disease treatment market with a 40.1% share in 2024
The antiviral drug segment is a major driver of the liver disease treatment market due to the high prevalence of viral hepatitis infections worldwide. Chronic hepatitis B and C infections affect hundreds of millions of people globally, creating a persistent demand for effective antiviral therapies. Innovations in direct-acting antivirals (DAAs) have significantly improved cure rates for hepatitis C, while nucleos(t)ide analogs have become the standard of care for hepatitis B, reducing the risk of liver cirrhosis and hepatocellular carcinoma.
For instance, in June 2025, Enanta Pharmaceuticals has received FDA approval for MAVYRET, an oral pangenotypic direct acting antiviral therapy, as the only eight-week treatment for adults and pediatric patients three years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis. The FDA has approved the treatment for viral infections and immunological diseases.
Additionally, government initiatives and WHO-led hepatitis elimination programs are promoting widespread screening and treatment, further boosting the uptake of antiviral drugs. The availability of oral, convenient, and highly effective antiviral regimens has made this segment one of the fastest-growing contributors to the liver disease therapeutics market.
Disease Type:The hepatitis segment is estimated to have a 41.2% of the liver disease treatment market share in 2024
The hepatitis disease type segment drives market growth due to the ongoing global burden of both hepatitis B (HBV) and hepatitis C (HCV) infections. Factors such as unsafe medical practices, blood transfusions, and high-risk behaviors contribute to the continued spread of these viral infections, particularly in developing regions. The rising prevalence of chronic hepatitis increases the demand for early diagnosis, long-term management, and treatment interventions, including antivirals, vaccines, and liver-protective therapies. Public health campaigns, increasing awareness, and government-supported vaccination programs for hepatitis B are also stimulating growth in this segment, making hepatitis-related therapies a cornerstone of the liver disease treatment market.
Geographical Analysis
North America dominates the global liver disease treatment market with a 43.5% in 2024
The liver disease treatment market in North America is primarily driven by the high prevalence of hepatitis C, liver cancer, and non-alcoholic fatty liver disease (NAFLD). Widespread awareness campaigns, advanced healthcare infrastructure, and strong reimbursement policies encourage early diagnosis and treatment. Additionally, continuous investment in research and development of novel antiviral and NASH-targeted therapies fuels market growth.
In the United States, the market is propelled by the high incidence of chronic liver diseases and obesity-related NAFLD/NASH cases. Federal initiatives such as the CDC’s hepatitis screening and elimination programs increase patient identification, leading to greater demand for antiviral drugs, immunosuppressants, and liver-protective therapies. The presence of leading pharmaceutical companies and clinical trial activity also contributes significantly.
For instance, in August 2025, The U.S. Food and Drug Administration has approved Wegovy (semaglutide) injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis (excessive scar tissue in the liver). MASH, also known as nonalcoholic steatohepatitis, is a serious liver disease.
Europe is the second region after North America which is expected to dominate the global liver disease treatment market with a 34.5% in 2024
Europe’s market growth is driven by the aging population, rising liver disease prevalence, and strong government support for healthcare initiatives. Countries like France, Italy, and the UK have implemented nationwide hepatitis vaccination and screening programs. The focus on early diagnosis and treatment of NAFLD/NASH and liver cancer creates steady demand for innovative therapeutics.
In Germany, the market is boosted by well-established healthcare infrastructure, high patient awareness, regulatory approvals and robust reimbursement frameworks. The country’s emphasis on chronic disease management, coupled with widespread hepatitis vaccination programs and access to advanced therapies, supports the adoption of antiviral drugs, biologics, and targeted treatments.
For instance, in August 2025, Madrigal Pharmaceuticals has received conditional marketing authorization from the European Commission for Rezdiffra, a novel therapeutic for metabolic dysfunction-associated steatohepatitis (MASH). The treatment is now the first and only approved therapy in the EU for adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
The Asia Pacific region is the fastest-growing region in the global liver disease treatment market, with a CAGR of 8.1% in 2024
The Asia Pacific market is driven by the high burden of viral hepatitis, particularly HBV and HCV, in countries like China and India. Rapid urbanization, lifestyle changes, and increasing rates of obesity contribute to NAFLD/NASH prevalence. Expanding healthcare access, government-led vaccination campaigns, and rising awareness about liver diseases further accelerate market growth.
Japan’s market growth is supported by the aging population and high prevalence of liver cancer and chronic hepatitis. Strong healthcare infrastructure, early diagnosis programs, and availability of advanced antiviral and immunomodulatory therapies contribute to increasing adoption. Government initiatives to reduce hepatitis-related mortality also enhance treatment uptake.
For instance, in September 2025, Japan's Ministry of Health, Labour and Welfare has approved Bylvay (odevixibat) for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare genetic disorder causing liver damage and potentially liver failure. Symptoms include severe itching, skin mutilation, sleep disruption, irritability, and impaired cognitive and social development. The condition severely impacts quality of life through debilitating symptoms.
Competitive Landscape
Top companies in the liver disease treatment market include AbbVie, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Astellas Pharma Inc., Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Akero Therapeutics and among others.
AbbVie: AbbVie is a key player in the liver disease treatment market, leveraging its strong portfolio of antiviral and liver-targeted therapies to address chronic hepatitis and related conditions. The company’s products, such as Viekira Pak and Mavyret, have been instrumental in providing highly effective treatment options for hepatitis C, offering shorter treatment durations and high cure rates. AbbVie also invests in research and development for emerging liver diseases, including NASH and autoimmune liver disorders, aiming to expand its therapeutic offerings beyond traditional antivirals.
The global liver disease treatment market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Treatment Type
2.4. Snippet by Disease Type
2.5. Snippet by Route of Administration
2.6. Snippet by Distribution Channel
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Increasing Incidence of Liver Diseases
3.1.1.2. Advancements in Drug Development
3.1.2. Restraints
3.1.2.1. Strict Regulatory Approvals
3.1.2.2. Antiviral Drug Resistance
3.1.3. Opportunity
3.1.3.1. Emerging Therapies for MASH/NASH
3.1.3.2. Integration of Weight Loss Drugs
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
5.1.2. Market Attractiveness Index, By Treatment Type
5.2. Antiviral Drugs*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Vaccines
5.4. Immunosuppressants
5.5. Corticosteroids
5.6. Targeted therapies
5.7. Chemotherapy drugs
5.8. Biologics
5.9. Others
6. LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Hepatitis*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Alcohol-related liver disease
6.4. Haemochromatosis
6.5. Primary biliary cholangitis
6.6. Others
7. LIVER DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Injectable
8. LIVER DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. LIVER DISEASE TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. AbbVie*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
12. FINANCIAL OVERVIEW
12.1. Company Revenue
12.1.1. Geographical Revenue Shares
12.1.1.1. Revenue Forecasts
12.1.2. Key Developments
12.1.2.1. Mergers & Acquisitions
12.1.2.2. Key Product Development Activities
12.1.2.3. Regulatory Approvals, etc.
12.1.3. SWOT Analysis
12.2. Gilead Sciences, Inc
12.3. F. Hoffmann-La Roche Ltd.
12.4. Bristol-Myers Squibb
12.5. Astellas Pharma Inc.
12.6. Intercept Pharmaceuticals
12.7. Madrigal Pharmaceuticals
12.8. Akero Therapeutics (LIST NOT EXHAUSTIVE)
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Treatment Type
2.4. Snippet by Disease Type
2.5. Snippet by Route of Administration
2.6. Snippet by Distribution Channel
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Increasing Incidence of Liver Diseases
3.1.1.2. Advancements in Drug Development
3.1.2. Restraints
3.1.2.1. Strict Regulatory Approvals
3.1.2.2. Antiviral Drug Resistance
3.1.3. Opportunity
3.1.3.1. Emerging Therapies for MASH/NASH
3.1.3.2. Integration of Weight Loss Drugs
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
5.1.2. Market Attractiveness Index, By Treatment Type
5.2. Antiviral Drugs*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Vaccines
5.4. Immunosuppressants
5.5. Corticosteroids
5.6. Targeted therapies
5.7. Chemotherapy drugs
5.8. Biologics
5.9. Others
6. LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Hepatitis*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Alcohol-related liver disease
6.4. Haemochromatosis
6.5. Primary biliary cholangitis
6.6. Others
7. LIVER DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Injectable
8. LIVER DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. LIVER DISEASE TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. AbbVie*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
12. FINANCIAL OVERVIEW
12.1. Company Revenue
12.1.1. Geographical Revenue Shares
12.1.1.1. Revenue Forecasts
12.1.2. Key Developments
12.1.2.1. Mergers & Acquisitions
12.1.2.2. Key Product Development Activities
12.1.2.3. Regulatory Approvals, etc.
12.1.3. SWOT Analysis
12.2. Gilead Sciences, Inc
12.3. F. Hoffmann-La Roche Ltd.
12.4. Bristol-Myers Squibb
12.5. Astellas Pharma Inc.
12.6. Intercept Pharmaceuticals
12.7. Madrigal Pharmaceuticals
12.8. Akero Therapeutics (LIST NOT EXHAUSTIVE)
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
LIST OF TABLES
Table 1 Global Liver Disease Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Liver Disease Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Liver Disease Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Liver Disease Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Liver Disease Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Liver Disease Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 8 Global Liver Disease Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 10 Global Liver Disease Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 12 Global Liver Disease Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 14 Global Liver Disease Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Liver Disease Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 17 North America Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 18 North America Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 19 North America Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 North America Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 22 Europe Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 23 Europe Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Europe Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 25 Europe Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 32 South America Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 33 South America Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 34 South America Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 35 South America Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 AbbVie: Overview
Table 42 AbbVie: Product Portfolio
Table 43 AbbVie: Key Developments
Table 44 Gilead Sciences, Inc: Overview
Table 45 Gilead Sciences, Inc: Product Portfolio
Table 46 Gilead Sciences, Inc: Key Developments
Table 47 F. Hoffmann-La Roche Ltd.: Overview
Table 48 F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 49 F. Hoffmann-La Roche Ltd.: Key Developments
Table 50 Bristol-Myers Squibb: Overview
Table 51 Bristol-Myers Squibb: Product Portfolio
Table 52 Bristol-Myers Squibb: Key Developments
Table 53 Astellas Pharma Inc.: Overview
Table 54 Astellas Pharma Inc.: Product Portfolio
Table 55 Astellas Pharma Inc.: Key Developments
Table 56 Intercept Pharmaceuticals: Overview
Table 57 Intercept Pharmaceuticals: Product Portfolio
Table 58 Intercept Pharmaceuticals: Key Developments
Table 59 Madrigal Pharmaceuticals: Overview
Table 60 Madrigal Pharmaceuticals: Product Portfolio
Table 61 Madrigal Pharmaceuticals: Key Developments
Table 62 Akero Therapeutics: Overview
Table 63 Akero Therapeutics: Product Portfolio
Table 64 Akero Therapeutics: Key Developments
Table 1 Global Liver Disease Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Liver Disease Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Liver Disease Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Liver Disease Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Liver Disease Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Liver Disease Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 8 Global Liver Disease Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 10 Global Liver Disease Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 12 Global Liver Disease Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 14 Global Liver Disease Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Liver Disease Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 17 North America Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 18 North America Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 19 North America Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 North America Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 22 Europe Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 23 Europe Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Europe Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 25 Europe Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 32 South America Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 33 South America Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 34 South America Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 35 South America Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Liver Disease Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Liver Disease Treatment Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Liver Disease Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Liver Disease Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Liver Disease Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 AbbVie: Overview
Table 42 AbbVie: Product Portfolio
Table 43 AbbVie: Key Developments
Table 44 Gilead Sciences, Inc: Overview
Table 45 Gilead Sciences, Inc: Product Portfolio
Table 46 Gilead Sciences, Inc: Key Developments
Table 47 F. Hoffmann-La Roche Ltd.: Overview
Table 48 F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 49 F. Hoffmann-La Roche Ltd.: Key Developments
Table 50 Bristol-Myers Squibb: Overview
Table 51 Bristol-Myers Squibb: Product Portfolio
Table 52 Bristol-Myers Squibb: Key Developments
Table 53 Astellas Pharma Inc.: Overview
Table 54 Astellas Pharma Inc.: Product Portfolio
Table 55 Astellas Pharma Inc.: Key Developments
Table 56 Intercept Pharmaceuticals: Overview
Table 57 Intercept Pharmaceuticals: Product Portfolio
Table 58 Intercept Pharmaceuticals: Key Developments
Table 59 Madrigal Pharmaceuticals: Overview
Table 60 Madrigal Pharmaceuticals: Product Portfolio
Table 61 Madrigal Pharmaceuticals: Key Developments
Table 62 Akero Therapeutics: Overview
Table 63 Akero Therapeutics: Product Portfolio
Table 64 Akero Therapeutics: Key Developments
LIST OF FIGURES
Figure 1 Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 3 Global Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 4 Global Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 6 Global Liver Disease Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Liver Disease Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 8 Antiviral Drugs Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Vaccines Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Immunosuppressants Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 11 Corticosteroids Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Targeted therapies Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Chemotherapy drugs Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Biologics Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Liver Disease Treatment Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 17 Hepatitis Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Alcohol-related liver disease Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 19 Haemochromatosis Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 Primary biliary cholangitis Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 Others Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Liver Disease Treatment Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 23 Oral Route of Administration in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 24 Injectable Route of Administration in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Liver Disease Treatment Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 26 Hospital Pharmacies Distribution Channel in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 27 Retail Pharmacies Distribution Channel in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 28 Online Pharmacies Distribution Channel in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 29 Global Liver Disease Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 30 North America Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 31 North America Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 32 North America Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 33 North America Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 34 North America Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 North America Liver Disease Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 36 Europe Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 37 Europe Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 38 Europe Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 39 Europe Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 40 Europe Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 41 Europe Liver Disease Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 42 Asia-Pacific Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 43 Asia-Pacific Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 44 Asia-Pacific Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 45 Asia-Pacific Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 46 Asia-Pacific Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 47 Asia-Pacific Liver Disease Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 48 South America Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 49 South America Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 50 South America Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 51 South America Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 52 South America Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 53 South America Liver Disease Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 54 Middle East and Africa Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 55 Middle East and Africa Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 56 Middle East and Africa Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 57 Middle East and Africa Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 58 Middle East and Africa Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 59 AbbVie: Financials
Figure 60 Gilead Sciences, Inc: Financials
Figure 61 F. Hoffmann-La Roche Ltd.: Financials
Figure 62 Bristol-Myers Squibb: Financials
Figure 63 Astellas Pharma Inc.: Financials
Figure 64 Intercept Pharmaceuticals: Financials
Figure 65 Madrigal Pharmaceuticals: Financials
Figure 66 Akero Therapeutics: Financials
Figure 1 Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 3 Global Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 4 Global Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 6 Global Liver Disease Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Liver Disease Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 8 Antiviral Drugs Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Vaccines Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Immunosuppressants Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 11 Corticosteroids Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Targeted therapies Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Chemotherapy drugs Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Biologics Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Liver Disease Treatment Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 17 Hepatitis Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Alcohol-related liver disease Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 19 Haemochromatosis Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 Primary biliary cholangitis Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 Others Disease Type in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Liver Disease Treatment Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 23 Oral Route of Administration in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 24 Injectable Route of Administration in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Liver Disease Treatment Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 26 Hospital Pharmacies Distribution Channel in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 27 Retail Pharmacies Distribution Channel in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 28 Online Pharmacies Distribution Channel in Global Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 29 Global Liver Disease Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 30 North America Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 31 North America Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 32 North America Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 33 North America Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 34 North America Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 North America Liver Disease Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 36 Europe Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 37 Europe Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 38 Europe Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 39 Europe Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 40 Europe Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 41 Europe Liver Disease Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 42 Asia-Pacific Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 43 Asia-Pacific Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 44 Asia-Pacific Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 45 Asia-Pacific Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 46 Asia-Pacific Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 47 Asia-Pacific Liver Disease Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 48 South America Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 49 South America Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 50 South America Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 51 South America Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 52 South America Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 53 South America Liver Disease Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 54 Middle East and Africa Liver Disease Treatment Market Value, 2022-2033 (US$ Billion)
Figure 55 Middle East and Africa Liver Disease Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 56 Middle East and Africa Liver Disease Treatment Market Share, By Disease Type, 2024 & 2033 (%)
Figure 57 Middle East and Africa Liver Disease Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 58 Middle East and Africa Liver Disease Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 59 AbbVie: Financials
Figure 60 Gilead Sciences, Inc: Financials
Figure 61 F. Hoffmann-La Roche Ltd.: Financials
Figure 62 Bristol-Myers Squibb: Financials
Figure 63 Astellas Pharma Inc.: Financials
Figure 64 Intercept Pharmaceuticals: Financials
Figure 65 Madrigal Pharmaceuticals: Financials
Figure 66 Akero Therapeutics: Financials
